Korea's GC Biopharma has signed a strategic memorandum of understanding (MOU) with the Thai Red Cross Society to collaborate on training and education for plasma derivative specialists, the Korean company said Monday.

The partnership builds on ties dating back to 2015, when GC Biopharma exported a plasma fractionation plant to Thailand. Under the new MOU, the two groups will jointly design and operate on-site training and fellowship programs for local production staff, with GC Biopharma transferring its manufacturing know-how and technologies.

Both parties also plan to explore additional projects, including potential technology transfer for plasma by-product processing methods.

“Strengthening local workforce capabilities through GC Biopharma’s specialized training is essential to maintaining the quality, safety and continuity of plasma derivative production in Thailand,” said Dootchai Chaiwanichsiri, director of the National Blood Centre at the Thai Red Cross. 

GC Biopharma is also expanding into the United States, the world’s largest immunoglobulin market, while targeting Southeast Asian countries that have not yet built self-sufficient plasma derivative systems.